The effectiveness and safeness of GLP-1 receptor agonists for treating hyperglycaemia after AIS has been demonstrated with exenatide at 9 h after AIS and continuing for 6 days to lower blood glucose (166). This evidence concerns the gene GLP1R and androgen insensitivity syndrome.